Results 101 to 110 of about 2,458 (200)

PI3K pathway activation in severe asthma is linked to steroid insensitivity and adverse outcomes [PDF]

Background: Patients with severe asthma may demonstrate reduced sensitivity to steroid treatment. However, the implications of this reduced responsiveness for clinical outcomes and the underlying mechanisms remain unclear.
Akamatsu, Taisuke, Hirai, Keita, Itoh, Kunihiko, Shirai, Toshihiro, Uehara, Sekiko   +4 more
core   +1 more source

Expert insights on Hodgkin’s lymphoma development in an activated PI3K delta syndrome patient undergoing leniolisib treatment [PDF]

Activated PI3K delta syndrome (APDS) is a primary immunodeficiency that is caused by mutations in the PI3K signalling pathway resulting in either gain-of-function or loss-of-function phenotypes of APDS 1 and 2.
Conti, Francesca, Moratti, Mattia, Sabattini, Elena, Zinzani, Pier Luigi   +3 more
core   +1 more source

Mechanistic Characterization of CDK9 Inhibition in T-Cell Lymphoma [PDF]

Mature T-cell lymphomas (mTCL) comprise a rare group of lymphoid malignancies with very diverse genetical, clinical, and pathological characteristics that are in many cases associated with poor prognosis.
Ksionsko, Nora Anna Maria
core   +1 more source

Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma [PDF]

, 2023
Ambrogio, Chiara, Arigoni, Maddalena, Calogero, Raffaele, Campisi, Marco, Chiarle, Roberto, Costa, Carlotta, Germena, Giulia, Hirsch, Emilio, Martinengo, Cinzia, Mastini, Cristina, Mota, Ines, Mura, Giulia, Olivero, Martina, Patrucco, Enrico, Peola, Silvia, Vissio, Elena, Voena, Claudia   +16 more
core   +1 more source

Second-line treatment for chronic lymphocytic leukemia: more questions than answers. [PDF]

, 2020
39 p.Introducción: El paradigma del tratamiento de la leucemia linfática crónica (LLC) en recaída/refractaria ha cambiado con la llegada de los nuevos fármacos orales con acción dirigida (fundamentalmente incorporados a nuestro arsenal terapéutico ...
García Villarroel, Pilar Leyre
core  

The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival

Haematologica
Not available.
Alexey V. Danilov, Ian W. Flinn, Matthew S. Davids, Beth Gregory, Ohad Bentur, David Sidransky, Jennifer R. Brown   +6 more
doaj   +1 more source

Kinase inhibitors in clinical practice: An expanding world [PDF]

, 2017
Kapur, Reuben, Pandey, Ruchi
core   +1 more source

Poster Sessions

HemaSphere, Volume 9, Issue S1, June 2025.
wiley   +1 more source

Hide and Seek: The Game Between Chronic Lymphocytic Leukaemia Cells and B Cell Receptor Signalling Inhibitors

European Medical Journal, 2017
The emergence of B cell receptor (BCR) kinase inhibitors has recently changed the treatment landscape in chronic lymphocytic leukaemia (CLL). The inhibitors that selectively target potential kinases downstream from BCR (particularly Bruton’s tyrosine ...
Kumudha Balakrishnan, Krishna Bojja, William Decker, Michael J. Keating   +3 more
doaj  

Duvelisib [PDF]

, 2020
openaire   +1 more source